Normal aging modulates the neurotoxicity of mutant huntingtin

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Diguet, Elsa ^a,b   Petit, Fanny ^a,b   Escartin, Carole ^a,b   Cambon, Karine ^a,b   Bizat, Nicolas ^a,b   Dufour, Noëlle ^a,b   Hantraye, Philippe ^a,b   Déglon, Nicole ^a,b   Brouillet, Emmanuel ^a,b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; HUNTINGTIN; LENTIVIRUS VECTOR; PHOSPHOPROTEIN DARPP 32;

ADULT; AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HISTOLOGY; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; IMMUNOREACTIVITY; IN VIVO STUDY; MALE; MUTANT; NERVE CELL; NEUROPIL; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT; REPORTER GENE; STEREOTACTIC PROCEDURE;

EID: 84864290342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004637     Document Type: Article

References (65)

1. Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59(5): 427-468.
2. The-Huntington-Disease-Collaborative-Research-Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72(6): 971-983.
3. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, et al. (1994) A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 330(20): 1401-1406.
4. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, et al. (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 101(10): 3498-3503.
5. Mattson MP, Magnus T (2006) Ageing and neuronal vulnerability. Nat Rev Neurosci 7(4): 278-294.
6. Vernace VA, Schmidt-Glenewinkel T, Figueiredo-Pereira ME (2007) Aging and regulated protein degradation: who has the UPPer hand? Aging Cell 6(5): 599-606.
7. Toescu EC, Verkhratsky A, Landfield PW (2004) Ca2+ regulation and gene expression in normal brain aging. Trends Neurosci 27(10): 614-620.
8. Beal MF (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58(4): 495-505.
9. Brouillet E, Jacquard C, Bizat N, Blum D (2005) 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 95(6): 1521-1540.
10. Clarke G, Collins RA, Leavitt BR, Andrews DF, Hayden MR, et al. (2000) A one-hit model of cell death in inherited neuronal degenerations. Nature 406(6792): 195-199.
11. de Almeida LP, Ross CA, Zala D, Aebischer P, Deglon N (2002) Lentiviralmediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 22(9): 3473-3483.
12. Arango M, Holbert S, Zala D, Brouillet E, Pearson J, et al. (2006) CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J Neurosci 26(17): 4649-4659.
13. Pardo R, Colin E, Regulier E, Aebischer P, Deglon N, et al. (2006) Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci 26(5): 1635-1645.
14. Palfi S, Brouillet E, Jarraya B, Bloch J, Jan C, et al. (2007) Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther 15(8): 1444-1451.
15. Colin E, Regulier E, Perrin V, Durr A, Brice A, et al. (2005) Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 21(6): 1478-1488.
16. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, et al. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19(7): 2522-2534.
17. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, et al. (1999) Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 46(6): 842-849.
18. Li H, Li SH, Johnston H, Shelbourne PF, Li XJ (2000) Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25(4): 385-389.
19. Li H, Li SH, Yu ZX, Shelbourne P, Li XJ (2001) Huntingtin aggregateassociated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci 21(21): 8473-8481.
20. Regulier E, Pereira de Almeida L, Sommer B, Aebischer P, Deglon N (2002) Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum Gene Ther 13(16): 1981-1990.
21. Dickstein DL, Kabaso D, Rocher AB, Luebke JI, Wearne SL, et al. (2007) Changes in the structural complexity of the aged brain. Aging Cell 6(3): 275-284.
22. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15(6): 965-977.
23. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9(9): 1259-1271.
24. Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, et al. (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96(3): 743-757.
25. Asanuma M, Nishibayashi S, Iwata E, Kondo Y, Nakanishi T, et al. (1996) Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor. Brain Res Mol Brain Res 41(1-2): 210-215.
26. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, et al. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97(12): 6763-6768.
27. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19(5): 233-238.
28. Deglon N, Aebischer P (2002) Lentiviruses as vectors for CNS diseases. Curr Top Microbiol Immunol 261: 191-209.
29. Deglon N, Hantraye P (2005) Viral vectors as tools to model and treat neurodegenerative disorders. J Gene Med 7(5): 530-539.
30. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277(5334): 1990-1993.
31. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90(3): 537-548.
32. Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, et al. (1999) Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet 8(7): 1227-1236.
33. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431(7010): 805-810.
34. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95(1): 55-66.
35. Li XJ, Li SH (2005) HAP1 and intracellular trafficking. Trends Pharmacol Sci 26(1): 1-3.
36. Li XJ, Li SH, Sharp AH, Nucifora FC Jr, Schilling G, et al. (1995) A huntingtinassociated protein enriched in brain with implications for pathology. Nature 378(6555): 398-402.
37. Kalchman MA, Koide HB, McCutcheon K, Graham RK, Nichol K, et al. (1997) HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet 16(1): 44-53.
38. Wanker EE, Rovira C, Scherzinger E, Hasenbank R, Walter S, et al. (1997) HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 6(3): 487-495.
39. Wang CE, Zhou H, McGuire JR, Cerullo V, Lee B, et al. (2008) Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol 181(5): 803-816.
40. Melov S (2004) Modeling mitochondrial function in aging neurons. Trends Neurosci 27(10): 601-606.
41. Loeb LA, Wallace DC, Martin GM (2005) The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations. Proc Natl Acad Sci U S A 102(52): 18769-18770.
42. Lu T, Pan Y, Kao SY, Li C, Kohane I, et al. (2004) Gene regulation and DNA damage in the ageing human brain. Nature 429(6994): 883-891.
43. Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, et al. (1997) Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 31(1): 53-64.
44. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, et al. (1993) Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 34(4): 609-616.
45. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408(6809): 239-247.
46. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 79(6): 1246-1249.
47. Bogdanov MB, Ferrante RJ, Kuemmerle S, Klivenyi P, Beal MF (1998) Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J Neurochem 71(6): 2642-2644.
48. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, et al. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22(5): 1592-1599.
49. Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, et al. (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta 1762(6): 616-626.
50. Browne SE, Beal MF (2006) Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 8(11-12): 2061-2073.
51. Sharpless NE, DePinho RA (2002) p53: good cop/bad cop. Cell 110(1): 9-12.
52. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, et al. (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47(1): 29-41.
53. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, et al. (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37(4): 349-350.
54. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, et al. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434(7029): 113-118.
55. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, et al. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127(1): 59-69.
56. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, et al. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 4(5): 349-362.
57. Zhou H, Cao F, Wang Z, Yu ZX, Nguyen HP, et al. (2003) Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the agedependent decrease in proteasome activity. J Cell Biol 163(1): 109-118.
58. Hottinger AF, Azzouz M, Deglon N, Aebischer P, Zurn AD (2000) Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci 20(15): 5587-5593.
59. de Almeida LP, Zala D, Aebischer P, Deglon N (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 8(3): 433-446.
60. Bizat N, Hermel JM, Boyer F, Jacquard C, Creminon C, et al. (2003) Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J Neurosci 23(12): 5020-5030.
61. Perrin V, Regulier E, Abbas-Terki T, Hassig R, Brouillet E, et al. (2007) Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol Ther 15(5): 903-911.
62. Coggeshall RE (1992) A consideration of neural counting methods. Trends Neurosci 15(1): 9-13.
63. Madeira MD, Andrade JP, Lieberman AR, Sousa N, Almeida OF, et al. (1997) Chronic alcohol consumption and withdrawal do not induce cell death in the suprachiasmatic nucleus, but lead to irreversible depression of peptide immunoreactivity and mRNA levels. J Neurosci 17(4): 1302-1319.
64. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231(4): 482-497.
65. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. (second edition).